Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1126 to 1140 of 1516 results for patients and public

  1. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.

    Technology appraisal guidance
    Published
    1 May 2024
    View recommendations

    Sections for TA967

  2. Tests in secondary care to identify people at high risk of ovarian cancer (HTG453)

    Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.

    HealthTech guidance
    Published
    15 November 2017
    View recommendations

    Sections for HTG453

  3. AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)

    NICE has developed a medtech innovation briefing (MIB) on the AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis

    Medtech innovation briefing
    Published
    15 December 2015

  4. Artificial intelligence for analysing chest CT images (MIB243)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .

    Medtech innovation briefing
    Published
    5 January 2021

  5. Secca System for faecal incontinence (MIB66)

    NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence

    Medtech innovation briefing
    Published
    24 May 2016

  6. Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment (HTG757)

    Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis.

    HealthTech guidance
    Published
    21 August 2025
    View recommendations

    Sections for HTG757

  7. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTG701)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.

    HealthTech guidance
    Published
    15 November 2023
    View recommendations

    Sections for HTG701

  8. Urinary tract infection (lower): antimicrobial prescribing (NG109)

    This guideline sets out an antimicrobial prescribing strategy for lower urinary tract infection (also called cystitis) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    31 October 2018
    View recommendations

    Sections for NG109

  9. Transperineal biopsy for diagnosing prostate cancer (HTG680)

    Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer.

    HealthTech guidance
    Published
    1 June 2023
    View recommendations

    Sections for HTG680

  10. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 February 2015

  11. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)

    Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.

    Technology appraisal guidance
    Published
    2 April 2025
    View recommendations

    Sections for TA1051

  12. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.

    Technology appraisal guidance
    Published
    25 November 2015
    View recommendations

    Sections for TA363

  13. The evidence for treating an acute migraine attack is adequate but, for treating subsequent attacks, is limited in quality and quantity. So, for treating acute migraine, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page . The evidence for preventing migraine is inadequate in quality. So, for preventing migraine, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    to support shared decision making, including NICE's information for the public. Ensure that people and their families and carers...

    Research recommendation
    Published
    7 November 2022

  14. Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion (HTG161)

    Evidence-based recommendations on laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. This involves using a special laser device to create a bypass without the need to temporarily interrupt the blood flow to the brain.

    HealthTech guidance
    Published
    27 February 2008
    View recommendations

    Sections for HTG161

  15. Photodynamic therapy for early-stage oesophageal cancer (HTG128)

    Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.

    HealthTech guidance
    Published
    13 December 2006
    View recommendations

    Sections for HTG128